Європейський Союз - фінська - EMA (European Medicines Agency)

biogen netherlands b.v. - natalitsumabin - multippeliskleroosi - selektiiviset immunosuppressantit - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 ja 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Європейський Союз - фінська - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - systeemiset bakteerilääkkeet, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. on otettava huomioon viralliset ohjeet antibioottien tarkoituksenmukaisesta käytöstä.

Європейський Союз - фінська - EMA (European Medicines Agency)

sandoz gmbh - natalitsumabin - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressantit - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 ja 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Фінляндія - фінська - Fimea (Suomen lääkevirasto)

sandoz a/s - cefuroxime sodium - injektio-/infuusiokuiva-aine liuosta varten - 1.5 g - kefuroksiimi

Фінляндія - фінська - Fimea (Suomen lääkevirasto)

glaxosmithkline (ireland) limited - cefuroximum axetilum - tabletti, kalvopäällysteinen - 250 mg - kefuroksiimi

Фінляндія - фінська - Fimea (Suomen lääkevirasto)

orion corporation - cefuroxime sodium - injektio/infuusiokuiva-aine liuosta/suspensiota varten - 1.5 g - kefuroksiimi

Фінляндія - фінська - Fimea (Suomen lääkevirasto)

orion corporation - cefuroxime sodium - injektio/infuusiokuiva-aine liuosta/suspensiota varten - 750 mg - kefuroksiimi

Фінляндія - фінська - Fimea (Suomen lääkevirasto)

sandoz a/s sandoz a/s - cefuroximum natricum - injektiokuiva-aine liuosta/suspensiota varten - 250 mg - kefuroksiimi

Фінляндія - фінська - Fimea (Suomen lääkevirasto)

sandoz a/s sandoz a/s - cefuroximum natricum - injektiokuiva-aine liuosta/suspensiota varten - 750 mg - kefuroksiimi

Фінляндія - фінська - Fimea (Suomen lääkevirasto)

sandoz a/s sandoz a/s - cefuroximum natricum - injektiokuiva-aine, liuosta varten - 1500 mg - kefuroksiimi